Spatial Immune Organization Associates with Response to CD40 Agonism in BCG-Unresponsive Non–Muscle-Invasive Bladder Cancer: A Phase I Trial

PURPOSE: CD40 agonists activate dendritic cells (DCs) and promote T-cell antitumor immunity, but clinical development has been limited by systemic toxicity and incomplete understanding of determinants of response. In this phase I study (NCT05126472), we evaluated the safety, preliminary clinical activity, and spatial immune correlates of response to intravesical Fc-optimized CD40 agonist 2141-V11 in 25 patients with Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC). PATIENTS AND METHODS: Patients received weekly intravesical instillations for 3 weeks, with retreatment at weeks 13 and 25 based on disease status. Primary objectives were safety, tolerability, and determination of the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D). Secondary endpoints included pharmacokinetics and preliminary clinical activity. Exploratory endpoints including multiplex spatial profiling on tumor specimens to define correlates of response. RESULTS: Intravesical 2141-V11 was well tolerated, and the MTD was not reached. The RP2D was established at 70 mg. Preliminary clinical activity was observed in 40% of patients, with a median response duration of 20 months. Clinical response was associated with distinct organization of tertiary lymphoid structures, characterized by the presence of DC-CXCL13+ CD4+ and CD8+ T cell triads. Following treatment, responders exhibited decreased proximity between DCs and regulatory T cells (Tregs), whereas non-responders exhibited increased DC-Treg proximity. CONCLUSIONS: Intravesical 2141-V11 demonstrated a favorable safety profile and preliminary antitumor activity. Spatial profiling revealed immune-cell organizations associated with clinical response, identifying candidate biomarkers and potential strategies for therapeutic combinations. These findings support further clinical evaluation of intravesical 2141-V11 in phase II studies.

Authors

Institutions

Publication Details

Journal
Clinical Cancer Research
Published
2026-11-17
DOI
https://doi.org/10.1158/1078-0432.ccr-26-3256
Primary Topic
Bladder and Urothelial Cancer Treatments
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Spatial Immune Organization Associates with Response to CD40 Agonism in BCG-Unresponsive Non–Muscle-Invasive Bladder Cancer: A Phase I Trial

Jeffrey V. Ravetch, Hikmat A Al‐Ahmadie, Jeffrey L. Wong, Timothy F. Donahue et al.
3 links
Clinical Cancer Research
Bladder and Urothelial Cancer Treatments
article

Spatial Immune Organization Associates with Response to CD40 Agonism in BCG-Unresponsive Non–Muscle-Invasive Bladder Cancer: A Phase I Trial

Jeffrey V. Ravetch, Hikmat A Al‐Ahmadie, Jeffrey L. Wong, Timothy F. Donahue, Juan Carlos Angulo-Lozano, Lucas Blanchard, Karissa A. Whiting, David A. Knorr, Eugene J. Pietzak, Venkatraman Seshan, Jonathan E. Rosenberg, Melissa McCarter, Benjamin D. Greenbaum, Juan Carlos Osorio, Ved P. Sharma, Bernard H. Bochner, Steven Grudman, Morgan Tomberlin, Ning Yao, Andrew Mijacika, Syed M. Alam, Jessica Pfau, Robert Smith, Ali Ghasemzadeh, Carlo Sevilla
article en

Abstract

PURPOSE: CD40 agonists activate dendritic cells (DCs) and promote T-cell antitumor immunity, but clinical development has been limited by systemic toxicity and incomplete understanding of determinants of response. In this phase I study (NCT05126472), we evaluated the safety, preliminary clinical activity, and spatial immune correlates of response to intravesical Fc-optimized CD40 agonist 2141-V11 in 25 patients with Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC). PATIENTS AND METHODS: Patients received weekly intravesical instillations for 3 weeks, with retreatment at weeks 13 and 25 based on disease status. Primary objectives were safety, tolerability, and determination of the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D). Secondary endpoints included pharmacokinetics and preliminary clinical activity. Exploratory endpoints including multiplex spatial profiling on tumor specimens to define correlates of response. RESULTS: Intravesical 2141-V11 was well tolerated, and the MTD was not reached. The RP2D was established at 70 mg. Preliminary clinical activity was observed in 40% of patients, with a median response duration of 20 months. Clinical response was associated with distinct organization of tertiary lymphoid structures, characterized by the presence of DC-CXCL13+ CD4+ and CD8+ T cell triads. Following treatment, responders exhibited decreased proximity between DCs and regulatory T cells (Tregs), whereas non-responders exhibited increased DC-Treg proximity. CONCLUSIONS: Intravesical 2141-V11 demonstrated a favorable safety profile and preliminary antitumor activity. Spatial profiling revealed immune-cell organizations associated with clinical response, identifying candidate biomarkers and potential strategies for therapeutic combinations. These findings support further clinical evaluation of intravesical 2141-V11 in phase II studies.

Clinical Cancer Research
Memorial Sloan Kettering Cancer Center (US), Yale University (US), Rockefeller University (US)
V Foundation for Cancer Research
Good health and well-being
Bladder and Urothelial Cancer Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon